Christopher Cannon: Discontinuation vs. Continuation of Statin Therapy in Adults Aged Under 75
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn about a recent article by Fabrice Bonnet, published in The Lancet Healthy Longevity, adding:
“Small randomized trial of stopping statins vs continuing in the elderly (low than 75) showed no diff in mortality but the expected trends for higher risk (about 20-30% higher) for MI stroke and MACE events).
No quality of life benefit for ‘deprescribing’.
So – best to keep the statin going!”
Title: Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
Authors: Fabrice Bonnet, Pierre Poulizac, Nicolas Rousselot, Thierry Couffinhal, Gaël Galli, Driss Berdaï, Marie-Anne Vandenhende, Marine Rousset, Roxane Coueron, Antoine Bénard, Jean-Philippe Joseph

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments